Meny
 

Advanced Drug Delivery Systems in the Management of Cancer

Kamal Dua (Redaktør) ; Meenu Mehta (Redaktør) ; Terezinha de Jesus Andreoli Pinto (Redaktør) ; Lisa G. Pont (Redaktør) ; Kylie A. Williams (Redaktør) ; Michael Rathbone (Redaktør)

Advanced Drug Delivery Systems in the Management of Cancer discusses recent developments in nanomedicine and nano-based drug delivery systems used in the treatment of cancers affecting the blood, lungs, brain, and kidneys. Les mer
Vår pris
2616,-

(Paperback) Fri frakt!
Leveringstid: Sendes innen 21 dager

Paperback
Legg i
Paperback
Legg i
Vår pris: 2616,-

(Paperback) Fri frakt!
Leveringstid: Sendes innen 21 dager

Om boka

Advanced Drug Delivery Systems in the Management of Cancer discusses recent developments in nanomedicine and nano-based drug delivery systems used in the treatment of cancers affecting the blood, lungs, brain, and kidneys. The research presented in this book includes international collaborations in the area of novel drug delivery for the treatment of cancer. Cancer therapy remains one of the greatest challenges in modern medicine, as successful treatment requires the elimination of malignant cells that are closely related to normal cells within the body. Advanced drug delivery systems are carriers for a wide range of pharmacotherapies used in many applications, including cancer treatment. The use of such carrier systems in cancer treatment is growing rapidly as they help overcome the limitations associated with conventional drug delivery systems. Some of the conventional limitations that these advanced drug delivery systems help overcome include nonspecific targeting, systemic toxicity, poor oral bioavailability, reduced efficacy, and low therapeutic index.

This book begins with a brief introduction to cancer biology. This is followed by an overview of the current landscape in pharmacotherapy for the cancer management. The need for advanced drug delivery systems in oncology and cancer treatment is established, and the systems that can be used for several specific cancers are discussed. Several chapters of the book are devoted to discussing the latest technologies and advances in nanotechnology. These include practical solutions on how to design a more effective nanocarrier for the drugs used in cancer therapeutics. Each chapter is written with the goal of informing readers about the latest advancements in drug delivery system technologies while reinforcing understanding through various detailed tables, figures, and illustrations.

Advanced Drug Delivery Systems in the Management of Cancer is a valuable resource for anyone working in the fields of cancer biology and drug delivery, whether in academia, research, or industry. The book will be especially useful for researchers in drug formulation and drug delivery as well as for biological and translational researchers working in the field of cancer.

Fakta

Innholdsfortegnelse

1. Introduction to cancer cell biology 2. Current practice in cancer pharmacotherapy 3. Current practices in oncology drug delivery 4. Emerging need of advanced drug delivery systems in cancer 5. Target drug delivery in cancer 6. Material and strategies used in oncology drug delivery 7. Hydrogel based drug delivery systems for cancer therapy 8. Recent advances in drug formulation development for targeting lung cancer 9. Advanced drug delivery systems in lung cancer 10. Advanced drug delivery systems in breast cancer 11. Advance drug delivery systems in the treatment of ovarian cancer 12. Advanced drug delivery systems in blood cancer 13. Advanced drug delivery systems in kidney cancer 14. Advance drug delivery systems in glioblastoma 15. Advanced drug delivery systems in prostate cancer 16. Nanomedicine-based doxorubicin delivery for skin cancer with theranostic potential 17. Advanced drug delivery systems in liver cancer 18. Advanced drug delivery systems in hepatocellular carcinoma 19. Advanced drug delivery systems in oral cancer 20. Advance drug delivery system in pancreatic cancer 21. Advanced drug delivery system in colorectal cancer 22. Current strategies in targeted anticancer drug delivery systems to brain 23. Neuroblastoma: Current advancements and future therapeutics 24. Nanoparticulate systems and their translation potential for breast cancer therapeutics 25. Advancement on nanoparticle-based drug delivery systems for cancer therapy 26. Advances in polymeric nanoparticles for drug delivery systems in cancer: Production and characterization 27. Lipid-polymer hybrid nanocarriers for delivering cancer therapeutics 28. Advancements on microparticles-based drug delivery systems for cancer therapy 29. Microparticles for cancer therapy 30. Biosynthetic exosome nanoparticles isolation, characterization, and their diagnostic and therapeutic applications 31. Advances in delivery of nanomedicines and theranostics for targeting breast cancer 32. Bioresponsive nano-theranostics approaches for cancer targeting 33. Two-dimensional materials-based nanoplatforms for lung cancer management: Synthesis, properties, and targeted therapy 34. Cell and gene therapies - Emerging technologies and drug delivery systems for treating brain cancer 35. Targeting siRNAs in cancer drug delivery 36. Targeting micro-ribonucleic acid (miRNA) in cancer using advanced drug delivery systems 37. Organic nanocarriers for targeted delivery of anticancer agents 38. Targeting cancer using phytoconstituents-based drug delivery 39. Clinical trials in drug delivery for the treatment of cancer 40. Future prospects and challenges in cancer drug delivery

Om forfatteren

Kamal Dua is a Senior Lecturer, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney (UTS), has a research experience of over 12 years working in the field of drug delivery targeting inflammatory diseases and cancer. Dr. Dua is also a node leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step toward translation into clinics. Dr. Dua researches in two
complementary areas: drug delivery and immunology, specifically addressing how these disciplines can advance one another helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua's research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. Dr. Dua is also an adjunct assistant professor in the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Canada; Adjunct Fellow
with the NICM Health Research Institute at Western Sydney University, Australia and Honorary Research Associate with the Australia-China Relations Institute (UTS:ACRI) and Consultant at ULTI Pharmaceuticals. He also held a Conjoint Lecturer position with the School of Biomedical Sciences and Pharmacy, The University of Newcastle, Australia. He has also published more than 80 research articles in the peerreviewed international journals and authored or coauthored four books and various book chapters. Meenu Mehta is a research scholar at the Discipline of Pharmacy, Graduate School of Health, the University of Technology Sydney. Her research is focused in the area of pharmaceutical technologies developing novel drug delivery systems for chronic respiratory diseases such as asthma, chronic obstructive lung disease (COPD), and lung cancer. She has obtained her M. Pharm degree in Pharmaceutical
Sciences in India, where she has gained working experience in several areas such as drug development, analytical methods, pharmacognosy studies, microwave techniques, and nanotechnology-based novel drug delivery systems. Mehta has received various awards and carries an impressive bibliography of scientific papers published in journals of international repute. Terezinha de Jesus Andreoli Pinto is a Professor at the School of Pharmaceutical Sciences, University of Sao Paulo. Professor Terezinha holds more than 40 years of sound experience in academia and researches on parenterals (formulation, analytical, microbiological, and performance methods) and medical devices. Professor Terezinha authored 180 articles in scientific journals, more than 12 book chapters and also holds two patents. Alongside her career, Professor Terezinha took on management roles in the University, such as being dean of School of Pharmacy for two mandates (2004-2008 and 2012-2016) and also being chair of Deliberative Board of FURP-a pharmaceutical firm that manufactures products from the WHO Essential Medicines list, run by Sao Paulo State Government. Strong scientific skills allied to leadership and management allowed her to establish agreements with internationally prestigious institutions including the University of Alberta, Lisbon, and Bath. Under her supervision, the CONFAR Laboratory was set up, the only Brazilian state university laboratory accredited by the National Institute of Metrology, Quality and Technology (INMETRO) (ISO/IEC 17025) and, authorized by the National Agency of Sanitary Surveillance (ANVISA) and the Ministry of Agriculture, Livestock, and Supplies (MAPA), and is considered a reference both in Brazil and overseas, in the analytical area. Professor Terezinha is also involved with standard-setting activities in agencies such as Brazilian Pharmacopeia (as coordinator of the Brazilian Pharmacopeia Drug Product and Medical Devices technical committee, and currently member of Biological and Biotechnological Products Committee), International Standard Organization (ISO) as Brazilian Association of Technical Norms (ABNT) representative and also the United States Pharmacopeia stakeholder with participation in convention current cycle. Lisa G. Pont is a Professor in the Discipline of Pharmacy, Graduate School of Health at the University of Technology Sydney. Pont is a pharmacoepidemiologist with expertise in medicine utilization and health service research to evaluate, understand, and improve the quality and safety of medicine use in practice. Her research explores current practices and patterns of medicines use across populations with a focus on the safety and quality of prescribing and medicines use. Throughout her career, Professor Pont has received a number of awards including two national NPS MedicineWise awards in 2014 and in 2016 for her research. She is a registered pharmacist and was awarded the Society of Hospital Pharmacist of Australia Medal of Merit in 2018. Kylie A. Williams is a pharmacist and academic leader. She is a founding member of the Graduate School of Health at University of Technology Sydney (UTS), where she is currently the Head of Pharmacy and the Deputy Head of School Learning & Teaching. She has over 25 years of academic experience in learning and teaching, curricula development, research, and academic leadership. Professor Williams leads a research team focused on development, implementation, and evaluation of new models of pharmacy and health service delivery. Alongside her research expertise, Professor Williams is internationally recognized for her curriculum development, and has received a number of teaching grants and awards and has coauthored numerous teaching-related peer-reviewed journal articles, professional books, and educational articles for pharmacists. Michael J. Rathbone is founder and managing director of his own company, ULTI Pharmaceuticals, New Zealand. He is also an associate of the School, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, Australia. He was formerly professor of Pharmaceutical Technology and dean, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia. Prior to this he was associate professor of Pharmaceutics, School of Pharmacy, Griffith University, Australia where his responsibilities included Acting Head of School. Previous to his appointment at Griffith University, he was the director of Research and General Manager InterAg, New Zealand, where he spearheaded the companies veterinary controlled drug delivery research and directed their national and global collaborative research activities. Dr. Rathbone obtained his undergraduate degree in Pharmacy at Leicester Polytechnic (De Montfort University), UK (1980), and PhD in Pharmaceutics from the University of Aston, Birmingham, UK (1986). Dr. Rathbone has innovated many novel veterinary drug delivery systems, several of which have been registered on the New Zealand, Australian and United States markets. He is a fellow of the Controlled Release Society, has served on the Board of Directors of the CRS and has received several prestigious awards for his contribution to the science and technology of controlled release. He has edited eight books in the area of modified release drug delivery and 10 special theme issues of journals such as Advanced Drug Delivery Reviews and Journal of Controlled Release. His knowledge of the entire spectrum of innovation, product research & development, cGMP analysis, manufacturing scale-up, QC analysis, stability testing, and registration provides him with an extensive overview, and unparalleled experience of the veterinary pharmaceutical industry.